Interresant zijn de volgende 2 disclaimers die ik nooit eerder gezien heb in voorgaande jaren:
Even if the Company successfully introduces Rhucin or another of its future products new technologies from competitors can make Rhucin or any other products under development and Pharming’s technology obsolete. Several competitors are active in the market for therapeutic products with more resources and significantly greater experience in, amongst others, obtaining regulatory approvals. The above events may have a material adverse effect on Pharming’s business, financial position, and results of operations, prospects and market price of the Shares.
Pharming is dependent on its ability to recruit and retain management and key employees. Pharming depends to a large degree on the performance and expertise of its management and technical personnel. Competition for qualified employees is intense in the fields in which Pharming is engaged and there is no guarantee that qualified employees will not leave Pharming. The loss of one or more of these employees could lead to significant delays in product development and thus negatively influence Pharming’s business activities. Pharming’s continued success depends moreover on recruiting and retaining highly qualified employees in the future, especially in management and in the area of research and development. The loss of individual employees or failure to attract new highly qualified employees could have significant detrimental consequences for Pharming’s business and financial position.
Zeker in het licht van de huidige instabiliteit is het vasthouden/aantrekken van bovengenoemde personeelsleden zeer moeilijk aan het worden (zie vertrekkend management als eerste symptoom)